{
    "clinical_study": {
        "@rank": "166702", 
        "brief_summary": {
            "textblock": "To evaluate whether immune globulin and ganciclovir (DHPG) results in faster initial\n      response as compared to DHPG alone. To evaluate whether immune globulin and DHPG gives\n      longer duration of remission than DHPG alone (i.e. 16 weeks). To evaluate the toxicities of\n      the combination of DHPG and immune globulin as compared to those of DHPG alone. To evaluate\n      if there is a difference between the two groups in regard to survival, immune functions, and\n      CMV viremia and viruria."
        }, 
        "brief_title": "A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS", 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have the following:\n\n          -  First episode of sight-threatening CMV retinitis.\n\n          -  At least one pending culture for CMV from the blood or urine prior to entry.\n\n          -  Life expectancy > 6 months.\n\n          -  Karnofsky performance = or > 60.\n\n          -  Ability to understand the nature of the study, to comply with study requirements, and\n             to sign informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions are excluded:\n\n          -  Known selective IGA deficiency or antibodies against IgA.\n\n          -  History of previous episodes of sight-threatening CMV retinitis.\n\n        Patients with the following are excluded:\n\n          -  Previous episode of sight-threatening CMV retinitis.\n\n          -  Concomitant treatment with other investigational agents except ddI or ddC.\n\n          -  Life expectancy < 6 months.\n\n          -  Continued alcohol or drug abuse.\n\n          -  Known selective IgA deficiency and known to have antibodies against IgA.\n\n          -  Karnofsky performance <60.\n\n        Other investigational agents except ddI or ddC.\n\n        ddI ddC"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001999", 
            "org_study_id": "079A", 
            "secondary_id": "219-90"
        }, 
        "intervention": [
            {
                "intervention_name": "Globulin, Immune", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Ganciclovir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ganciclovir", 
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "keyword": [
            "Retinitis", 
            "Gamma-Globulins", 
            "Ganciclovir", 
            "Drug Therapy, Combination", 
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "Immunization, Passive"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20007"
                }, 
                "name": "Georgetown Univ Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001999"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "American National Red Cross", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1993"
    }, 
    "geocoordinates": {
        "Georgetown Univ Med Ctr": "38.895 -77.036"
    }
}